Michael A. Gold

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz et al. · New England Journal of Medicine · 2023 · 800 citations · Full text

Medicine, Oncology, Pharmacology +17

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Journal of Clinical Oncology · 2021 · 406 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 394 citations

Medicine, Oncology, Pharmacotherapy +13

Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study

Charles F. Levenback, Shamshad Ali, Robert L. Coleman et al. · Journal of Clinical Oncology · 2012 · 392 citations · Full text

Medicine, Oncology, Surgery +17

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12